BOXED O
WARNING O
: O
WARNING O
: O
BLEEDING O
RISK O
WARNING O
: O
BLEEDING O
RISK O
* O
Effient O
can O
cause O
significant O
, O
sometimes O
fatal B-NonOSE_AE
, O
bleeding B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

* O
Do O
not O
use O
Effient O
in O
patients O
with O
active O
pathological O
bleeding B-Not_AE_Candidate
or O
a O
history O
of O
transient B-Not_AE_Candidate
ischemic I-Not_AE_Candidate
attack I-Not_AE_Candidate
or O
stroke B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.1 O
, O
4.2 O
) O
] O
. O

* O
In O
patients O
> O
=75 O
years O
of O
age O
, O
Effient O
is O
generally O
not O
recommended O
, O
because O
of O
the O
increased O
risk O
of O
fatal B-NonOSE_AE
and O
intracranial B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
and O
uncertain O
benefit O
, O
except O
in O
high-risk O
situations O
( O
patients O
with O
diabetes B-Not_AE_Candidate
or O
a O
history O
of O
prior O
MI B-Not_AE_Candidate
) O
where O
its O
effect O
appears O
to O
be O
greater O
and O
its O
use O
may O
be O
considered O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

* O
Do O
not O
start O
Effient O
in O
patients O
likely O
to O
undergo O
urgent O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
. O

When O
possible O
, O
discontinue O
Effient O
at O
least O
7 O
days O
prior O
to O
any O
surgery O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Additional O
risk O
factors O
for O
bleeding B-NonOSE_AE
include O
: O
body O
weight O
< O
60 O
kg O
; O
propensity B-Not_AE_Candidate
to I-Not_AE_Candidate
bleed I-Not_AE_Candidate
; O
concomitant O
use O
of O
medications O
that O
increase O
the O
risk B-NonOSE_AE
of I-NonOSE_AE
bleeding I-NonOSE_AE
( O
e.g. O
, O
warfarin O
, O
heparin O
, O
fibrinolytic O
therapy O
, O
chronic O
use O
of O
non-steroidal O
anti-inflammatory O
drugs O
[ O
NSAIDs O
] O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Suspect O
bleeding B-NonOSE_AE
in O
any O
patient O
who O
is O
hypotensive B-NonOSE_AE
and O
has O
recently O
undergone O
coronary O
angiography O
, O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
, O
CABG O
, O
or O
other O
surgical O
procedures O
in O
the O
setting O
of O
Effient O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
If O
possible O
, O
manage O
bleeding B-NonOSE_AE
without O
discontinuing O
Effient O
. O

Discontinuing O
Effient O
, O
particularly O
in O
the O
first O
few O
weeks O
after O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
increases O
the O
risk O
of O
subsequent O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
BLEEDING O
RISK O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Effient O
can O
cause O
significant O
, O
sometimes O
fatal O
, O
bleeding O
( O
5.1 O
, O
5.2 O
, O
6.1 O
) O
. O

* O
Do O
not O
use O
Effient O
in O
patients O
with O
active O
pathological O
bleeding O
or O
a O
history O
of O
transient O
ischemic O
attack O
or O
stroke O
( O
4.1 O
, O
4.2 O
) O
. O

* O
In O
patients O
> O
=75 O
years O
of O
age O
, O
Effient O
is O
generally O
not O
recommended O
, O
except O
in O
high-risk O
patients O
( O
diabetes O
or O
prior O
MI O
) O
, O
where O
its O
use O
may O
be O
considered O
( O
8.5 O
) O
. O

* O
Do O
not O
start O
Effient O
in O
patients O
likely O
to O
undergo O
urgent O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
. O

When O
possible O
, O
discontinue O
Effient O
at O
least O
7 O
days O
prior O
to O
any O
surgery O
( O
5.2 O
) O
. O

* O
Additional O
risk O
factors O
for O
bleeding O
include O
: O
body O
weight O
< O
60 O
kg O
; O
propensity O
to O
bleed O
; O
concomitant O
use O
of O
medications O
that O
increase O
the O
risk O
of O
bleeding O
( O
5.1 O
) O
. O

* O
Suspect O
bleeding O
in O
any O
patient O
who O
is O
hypotensive O
and O
has O
recently O
undergone O
coronary O
angiography O
, O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
, O
CABG O
, O
or O
other O
surgical O
procedures O
in O
the O
setting O
of O
Effient O
( O
5.1 O
) O
. O

* O
If O
possible O
, O
manage O
bleeding O
without O
discontinuing O
Effient O
. O

Stopping O
Effient O
increases O
the O
risk O
of O
subsequent O
cardiovascular O
events O
( O
5.3 O
) O
. O

